AB
TVRD

Amalgamated Bank’s Tvardi Therapeutics TVRD Stock Holding History

Amalgamated Bank’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-169
Closed -$1K – 2939
2025
Q4 		$1K Buy
169
+52
+44% +$466 ﹤0.01% 2970
2025
Q3 		$5K Hold
117
– – ﹤0.01% 2807
2025
Q2 		$3K Buy
+117
New +$2.77K ﹤0.01% 2946
2024
Q2 		– Sell
-42
Closed -$1K – 3130
2024
Q1 		$1K Sell
42
-73
-63% -$1.89K ﹤0.01% 2945
2023
Q4 		$3K Sell
115
-13
-10% -$538 ﹤0.01% 2972
2023
Q3 		$8K Hold
128
– – ﹤0.01% 2939
2023
Q2 		$13K Sell
128
-445
-78% -$61.3K ﹤0.01% 2918
2023
Q1 		$101K Buy
573
+9
+2% +$3.01K ﹤0.01% 2054
2022
Q4 		$218K Hold
564
– – ﹤0.01% 1830
2022
Q3 		$190K Buy
564
+20
+4% +$7.24K ﹤0.01% 1877
2022
Q2 		$179K Buy
544
+14
+3% +$4.91K ﹤0.01% 1921
2022
Q1 		$232K Sell
530
-32
-6% -$13.1K ﹤0.01% 1885
2021
Q4 		$246K Sell
562
-22
-4% -$11.1K ﹤0.01% 1898
2021
Q3 		$325K Sell
584
-11
-2% -$5.52K ﹤0.01% 1812
2021
Q2 		$305K Buy
+595
New +$377K ﹤0.01% 1877

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Amalgamated Bank's TVRD Position: Q1 2026 in Review

Amalgamated Bank sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 169 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in TVRD in Q2 2021 and held it in 15 quarters. The position peaked at $325K in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Amalgamated Bank reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 169 Tvardi Therapeutics shares in Q1 2026, an estimated $1K.
  • Amalgamated Bank first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 15 quarters.
  • Amalgamated Bank's Tvardi Therapeutics position peaked at $325K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.